Unicycive Therapeutics Ownership
| UNCY Stock | USD 0.68 0.03 4.62% |
Unicycive |
Unicycive Stock Ownership Analysis
About 60.0% of the company outstanding shares are owned by institutional investors. The book value of Unicycive Therapeutics was at this time reported as 0.28. The company recorded a loss per share of 0.46. Unicycive Therapeutics had not issued any dividends in recent years. Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. The company was incorporated in 2016 and is based in Los Altos, California. Unicycive Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 9 people. For more information please call the company at 650 351 4495 or visit https://unicycive.com.Besides selling stocks to institutional investors, Unicycive Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Unicycive Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Unicycive Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Unicycive Therapeutics Quarterly Liabilities And Stockholders Equity |
|
About 6.0% of Unicycive Therapeutics are currently held by insiders. Unlike Unicycive Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Unicycive Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Unicycive Therapeutics' insider trades
Unicycive Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Unicycive Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Unicycive Therapeutics backward and forwards among themselves. Unicycive Therapeutics' institutional investor refers to the entity that pools money to purchase Unicycive Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-12-31 | 524.5 K | Xtx Topco Ltd | 2024-12-31 | 171.5 K | State Street Corp | 2024-12-31 | 125.2 K | Goldman Sachs Group Inc | 2024-12-31 | 73.6 K | Blackrock Inc | 2024-12-31 | 72.3 K | Northern Trust Corp | 2024-12-31 | 58.2 K | Creative Planning Inc | 2024-12-31 | 22.7 K | Hrt Financial Llc | 2024-12-31 | 22.1 K | Tandem Capital Management Corp | 2024-12-31 | 15.5 K | Great Point Partners Llc | 2024-12-31 | 11 M | Nantahala Capital Management, Llc | 2024-12-31 | 10.4 M |
Unicycive Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Unicycive Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Unicycive Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Unicycive Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Unicycive Therapeutics Outstanding Bonds
Unicycive Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Unicycive Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Unicycive bonds can be classified according to their maturity, which is the date when Unicycive Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| UniCredit 7296 percent Corp BondUS904678AQ20 | View | |
| UCGIM 2569 22 SEP 26 Corp BondUS904678AU32 | View | |
| UniCredit 5459 percent Corp BondUS904678AS85 | View | |
| UNICREDIT SPA 5861 Corp BondUS904678AF64 | View | |
| UCGIM 3127 03 JUN 32 Corp BondUS904678AY53 | View | |
| UCGIM 1982 03 JUN 27 Corp BondUS904678AW97 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Unicycive Stock Analysis
When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.